{"name":"Crinetics Pharmaceuticals","slug":"crinetics","ticker":"CRNX","exchange":"NASDAQ","domain":"crinetics.com","description":"Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.","hq":"San Diego, CA","founded":0,"employees":"594","ceo":"R. Scott Struthers","sector":"Rare Endocrinology","stockPrice":39.73,"stockChange":1.32,"stockChangePercent":3.44,"marketCap":"$4.2B","metrics":{"revenue":1039000,"revenueGrowth":-74.1,"grossMargin":0,"rdSpend":332058000,"netIncome":-465317000,"cash":1027889024,"dividendYield":0,"peRatio":-9.7,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2025-01-01","label":"Palsonify first approved","drug":"Palsonify","drugSlug":"paltusotine","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-01-01","label":"Palsonify PHASE3 readout","drug":"Palsonify","drugSlug":"paltusotine","type":"phase3_readout","sentiment":"neutral"},{"date":"2034-06-01","label":"CRN04777 patent cliff ($1.2B at risk)","drug":"CRN04777","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"CRN04894 patent cliff ($500M at risk)","drug":"CRN04894","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Palsonify","genericName":"PALTUSOTINE","slug":"paltusotine","indication":"acromegaly","status":"marketed"}]}],"pipeline":[{"name":"Palsonify","genericName":"PALTUSOTINE","slug":"paltusotine","phase":"marketed","mechanism":"Palsonify works by binding to and inhibiting a specific protein involved in the regulation of growth hormone production.","indications":["acromegaly"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Crinetics Pharmaceuticals Announces FDA Acceptance of New Drug Application for CRN04777","summary":"The FDA has accepted the NDA for CRN04777, a potent and selective SSTR5 antagonist for the treatment of acromegaly.","drugName":"CRN04777","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results","summary":"The company reported a net loss of $23.4 million for the third quarter of 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-08-14","type":"deal","headline":"Crinetics Pharmaceuticals Announces Collaboration with Pfizer to Develop CRN04894","summary":"The company has entered into a collaboration with Pfizer to develop CRN04894, a potent and selective SSTR2 antagonist for the treatment of acromegaly and other rare endocrine disorders.","drugName":"CRN04894","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNQlItOWVFZWdiNVZyaEdKZDc2WncyUGtCX1lHaWNQUzNxRGVPak1MVGtXbV9UQ0xRdWVrclQyTnFuTzdnNS1Wb1pWNHJfWXpMSjM1TmtEUmpkNWRSRm9mZ2hZbEVLLUpqMTZtdkVoV1Zmak5ObHkwcGJXRUwwQk1DeERtT2dpRjlLOFlUSQ?oc=5","date":"2026-03-23","type":"pipeline","source":"MSN","summary":"Crinetics Pharma COO to step down - MSN","headline":"Crinetics Pharma COO to step down","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"pipeline","source":"simplywall.st","summary":"Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Volatility - simplywall.st","headline":"Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Volatility","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxNR1hfMEZEUzdxaDRfc1k5Y295cXFQdHVZRlFGM3Q2T2s4TldxNi1yUEU4eGVjUThWWjByaTZTYVhaeFZ6WFM5bzZzc0FrSVRnOXF0ak1rakU5R1V4X0s3MmxhX2M5b2ROTEpzdXI0SU1CazdFSEI5SHJLQ0ZxS3lycUtzVjJDbnB6S09lXzFXdzZDZDhyNEdOcjJjOTdOcHFiVzZTRUF1b2lZbUl3TUcyYnJlMFF2NGY0OHp2cWFJOTFpLVFTbW56XzV6TFRMT2pIcXBKdlY0VVNWZlpZckNvNE93?oc=5","date":"2026-01-05","type":"pipeline","source":"GlobeNewswire","summary":"Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock - GlobeNewswire","headline":"Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNbVg4QzhuZkdCWG5NNGdvSktqVnhLMmVWanB0N2Z6VDEyVV95eHhFMFktUW1TeC1KcmxEUXpjQUg2NHE4aG1FdUVjM1BRXzNjVVNudDVWT2JVcm40MmNHQjlHWXV1TjJ6a0oxcnNjei14TXB1cDc0enhDakd6ckd1ZXB3OVkzZkREUEZXQkJfODlJY0RwYmpfMTJvY2NfWjhDVjh2N0ExRU1yTXZvY3VEODRiY2JCckZCUHF2VVVB?oc=5","date":"2026-01-04","type":"pipeline","source":"Stock Titan","summary":"Live briefing to share atumelnant results in congenital adrenal hyperplasia - Stock Titan","headline":"Live briefing to share atumelnant results in congenital adrenal hyperplasia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQWkFnZEFnc0pta05qZHRfRk5UQzFHeVVrWDNkZUxmUkZXdE5LT1BoV2pOOHhFQVBQNG9QZ3VITjd4b3dQazFGc2NKRkI3ZllBVzZ6bUp1SU1oQ1lVcFRERE5uX1NGZW1pRmIzWFE3NTlrd1NfSDFXQ3FFU3N1RzJXVmJ6dFBmaTNkbF85Mi15d3oteDB5WFE?oc=5","date":"2025-10-30","type":"regulatory","source":"Seeking Alpha","summary":"Crinetics Pharmaceuticals: Its Post-FDA Approval Future (NASDAQ:CRNX) - Seeking Alpha","headline":"Crinetics Pharmaceuticals: Its Post-FDA Approval Future (NASDAQ:CRNX)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNVFpaLU5zY1VzQXNOOWNiZEQ2Q0NadzU4Q1RFVkJXTUR6c3JkWl9XR1p4cXI5ZkdVaUxia0RfUVFKdjFXRVphaE9xeHF0Q1pHN3lzX0tOUDN5YlVZdERweGhkVlUzY29PWVpUcjNZc0xNRXhiVDBXNnVfRnBaTC1RN3FvWGJ0NzJMNWNOUWd3?oc=5","date":"2025-09-30","type":"regulatory","source":"Yahoo Finance","summary":"JMP Backs Crinetics Pharmaceuticals, Inc. (CRNX) With Big Upside Post-Approval - Yahoo Finance","headline":"JMP Backs Crinetics Pharmaceuticals, Inc. (CRNX) With Big Upside Post-Approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOZmtOeWZvZXFiYmFVX3ZJMVpyX2ZGNm9WRDk0bWczWndRSHNobTNjM3NKSEZGWDJ2S2JDYmtaOWF6T3ByLVF6S1JiVzFuZ3pMWmdjOEJINld4bHhnX1FNNFRNYVhiYmZISl9fNVg0bVpmZUtXd3NXYjFkeE1qY3cxZE93?oc=5","date":"2025-09-29","type":"regulatory","source":"Yahoo Finance","summary":"Crinetics Pharma (CRNX) Flies 35% Higher on FDA Approval of Acromegaly Drug - Yahoo Finance","headline":"Crinetics Pharma (CRNX) Flies 35% Higher on FDA Approval of Acromegaly Drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOblQ4aWVDUVhMdmVaWFBBMkxIb0JHVFZ4Y2NTNHFiZ1NiRVhRVF9jaThmeWpXRjlxZEVtd3dKTnFWX1U5TnktNjlDY0Z5ZV9IUG95VklZV2pfQlJJNkFPZUVUWDBHR2VrYUlVZlRReWNFSVFNc0lqYmNtUE5JVjhxdm5NUXVmR281RmRF?oc=5","date":"2025-09-28","type":"deal","source":"The Motley Fool","summary":"Is Crinetics Pharmaceuticals Stock a Buy? - The Motley Fool","headline":"Is Crinetics Pharmaceuticals Stock a Buy?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQNmt4N01naTRDZDR0VmtjVWhXTWFEZS1uc2RwbkZKbWhpZmE5RGtKajVaeDYzRWQtUEpXZ09pc3V0SjRyYi11dFBGbEJPbGRoYU9UWWVycnV1WDV6ZGhlWVBaNzJrY3FtVWxVYV9acGtfRHNHVDR4TERHWXFpQU5CUE1wMXZNaDN2RHc?oc=5","date":"2025-09-26","type":"regulatory","source":"Yahoo Finance","summary":"FDA Approves Crinetics Pharma's First Daily Pill For Rare Growth Disorder - Yahoo Finance","headline":"FDA Approves Crinetics Pharma's First Daily Pill For Rare Growth Disorder","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOM0RsYzl3WExWSjNsZWJFSlV2cWFBbjVZU2pId09oYlZHN3pJOW9zT1RvVHhLV3RFOUJPU0tkRmlPV1BaRmJUcmhDNV9fejdVRkJxYnNnY1JVNko1Qk9mQnZHbTR3LUxvVVZiZGhndDk1ZDB6aEFJV2k1NkVucE9yaG1WbUtlQUhVdnBhUWJsUjNnTXptdm1NcWF1QldpLTVXdmFOcm5KTkZUM2MwOHhqazdIdzluR3RBN1NzWg?oc=5","date":"2025-06-16","type":"pipeline","source":"Seeking Alpha","summary":"Crinetics: Highly Priced Biotech Awaits PDUFA On Acromegaly Drug (NASDAQ:CRNX) - Seeking Alpha","headline":"Crinetics: Highly Priced Biotech Awaits PDUFA On Acromegaly Drug (NASDAQ:CRNX)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-04-23","type":"pipeline","source":"simplywall.st","summary":"Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans - simplywall.st","headline":"Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans","sentiment":"neutral"}],"patents":[{"drugName":"CRN04777","drugSlug":"somatostatin-receptor-5-antagonist","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"CRN04894","drugSlug":"somatostatin-receptor-2-antagonist","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":500000000}],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Novartis","Pfizer","Merck"],"therapeuticFocus":["Rare Endocrinology"],"financials":{"source":"sec_edgar","revenue":1039000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":1039000,"period":"2024-12-31"},{"value":4013000,"period":"2023-12-31"},{"value":4737000,"period":"2022-12-31"},{"value":4737000,"period":"2022-12-31"},{"value":1078000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":332058000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-465317000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1126257000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":39.73,"previousClose":38.41,"fiftyTwoWeekHigh":57.99,"fiftyTwoWeekLow":24.1,"fiftyTwoWeekRange":"24.1 - 57.99","fiftyDayAverage":41.84,"twoHundredDayAverage":39.86,"beta":0.31,"enterpriseValue":3042383616,"forwardPE":-9.7,"priceToBook":3.83,"priceToSales":540.53,"enterpriseToRevenue":395.32,"enterpriseToEbitda":-5.93,"pegRatio":0,"ebitda":-512879008,"ebitdaMargin":0,"freeCashflow":-206911632,"operatingCashflow":-377921984,"totalDebt":48541000,"debtToEquity":4.9,"currentRatio":12.32,"returnOnAssets":-25.2,"returnOnEquity":-40.2,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":14,"targetMeanPrice":83.5,"targetHighPrice":97,"targetLowPrice":55,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2,"institutionHeldPercent":110.2,"sharesOutstanding":104705330,"floatShares":96248280,"sharesShort":15363638,"shortRatio":15.34,"shortPercentOfFloat":14.7,"epsTrailing":-4.95,"epsForward":-4.08,"revenuePerShare":0.08,"bookValue":10.38,"officers":[{"age":63,"name":"Dr. R. Scott Struthers Ph.D.","title":"Founder, President, CEO & Director"},{"age":58,"name":"Dr. Stephen F. Betz Ph.D.","title":"Co-Founder & Chief Scientific Officer"},{"age":53,"name":"Mr. Jeff E. Knight M.P.H.","title":"Chief Development & Operating Officer"},{"age":50,"name":"Mr. Tobin C. Schilke","title":"Chief Financial Officer"},{"age":null,"name":"Ms. Gayathri  Diwakar","title":"Senior Director of Investor Relations"},{"age":null,"name":"Ms. Garlan  Adams J.D.","title":"Chief Legal Officer & Corporate Secretary"},{"age":null,"name":"Ms. Adriana  Cabre M.B.A.","title":"Chief Human Resources Officer"},{"age":62,"name":"Dr. Alan S. Krasner M.D.","title":"Chief Endocrinologist"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.crinetics.com","phone":"858 450 6464"}}